What Fungram Treats: Main Uses and Benefits

Fungram is used across therapeutic domains where additional symptomatic support is needed for managing infections caused by various fungal and yeast species, notably Candida and Cryptococcus. This medicine is used to treat serious, widespread infections that affect multiple organs and may be applied when appropriate to help reduce the risk of them in high-risk patients.

Treating Deep-Seated and Systemic Fungal Diseases

Fungram is considered relevant for the management of serious, pervasive infections, particularly those that have spread throughout the body, such as candidemia and Cryptococcal meningitis. This application provides support that helps ease the overall symptom burden and is relevant in contexts involving heightened systemic burden.

---

Quick Fact: Relief for Symptoms related to Systemic Imbalance

Supporting Recurrent Infection and Prophylaxis in High-Risk Patients

Fungram is applied in clinical settings that involve acute or unstable symptom patterns, and is used for conditions that present with recurrent or episodic manifestations, such as frequently recurring vaginal candidiasis. It may also be part of symptomatic management to help reduce the risk of fungal manifestations in immunocompromised patients, assisting with maintaining functional stability.

Regulatory References

1. US National Library of Medicine (NIH) MedlinePlus overview

Fungram (Griseofulvin) is an oral antifungal medication used to treat dermatophyte infections of the skin, hair, and nails, such as ringworm, athlete’s foot, and fungal nail infections, when topical treatments are inadequate or inappropriate. It is not effective against yeast infections (candidiasis), Pityriasis versicolor, or bacterial infections.

---

Contraindications and Cautions

Fungram is contraindicated and must not be used by individuals with the following pre-existing conditions:

• Porphyria: A group of disorders affecting the nervous system or skin.
• Hepatocellular failure: Severe liver disease or failure.
• Hypersensitivity to griseofulvin or any component of the formulation.

Special caution and consultation with a healthcare professional are required for patients with a history of lupus erythematosus or lupus-like syndromes, as Fungram may exacerbate these conditions. Periodic monitoring of liver, kidney, and blood cell functions is recommended for those on prolonged therapy.

Use in Specific Populations

Population	Recommendation
Pregnancy	Contraindicated. Fungram may cause fetal harm and is associated with potential teratogenic effects. Effective non-hormonal contraception must be used during treatment and for at least one month after the last dose.
Breastfeeding	Consult a doctor. Safety during breastfeeding has not been established.
Children	Used to treat dermatophyte infections, such as tinea capitis. Dosing varies by formulation and age; use should be guided by a doctor.

Fungram Interactions with other medicines and products

Fungram (Fluconazole) has a comprehensive interaction profile, documented by regulatory authorities, which primarily involves alterations in the plasma concentration of co-administered medicines.

Formal Contraindicated Combinations

Certain combinations are formally prohibited due to the risk of serious adverse effects, primarily QT prolongation and Torsades de pointes. These restrictions are non-negotiable. Contraindicated combinations include Cisapride, Astemizole, Erythromycin, Pimozide, and Quinidine. The co-administration of Terfenadine is also prohibited when the Fungram dose is 400 mg/day or higher.

Pharmacokinetic and Exposure Changes

Fungram co-administration is officially documented to increase the exposure (AUC and C max) of several medicines, including Voriconazole, Tofacitinib, and Oral Contraceptives. Conversely, certain substances can decrease Fungram exposure; for example, Rifampicin is noted to reduce Fungram's AUC and shorten its half-life.

Population and General Interaction Notes

• Food and Antacids: Fungram absorption is not clinically impaired by co-administration with food or antacids.
• Renal Function: The drug's pharmacokinetics are markedly affected by reduced renal function, which can alter its systemic exposure.
• Pharmacodynamic Risk: An increased risk of cardiotoxicity or QT prolongation is officially noted when Fungram is co-administered with medicines such as Amiodarone or Halofantrine.

How Fungram Works

Fungram's action involves a biochemical alteration that compromises the structural integrity of the fungal organism. The mechanism of action is fungistatic, characterized by the suppression of fungal growth rather than direct cellular destruction.

---

Targeted Inhibition of Fungal Enzyme

Fungram (Fluconazole) initiates its effect by selectively inhibiting the enzyme lanosterol 14alpha-demethylase (CYP51), a cytochrome P450 enzyme in the fungal cell. This molecular target is an enzyme in the fungal cell's sterol biosynthesis pathway, regulating the production of membrane components.

---

Cascade Leading to Membrane Disruption

Inhibition of the 14alpha-demethylase prevents the conversion of lanosterol into ergosterol, the necessary sterol component of the fungal membrane . Simultaneously, the disruption causes the accumulation of toxic 14alpha-methyl sterols within the cell. The resulting physiological consequence is a structurally defective and hyper-permeable fungal cell membrane, leading to altered cellular homeostasis and the inhibition of fungal proliferation.

How to Use Fungram — Official Administration Guidelines

This section outlines the administration instructions for Fungram.

Fungram is supplied in several forms, each with specific administration requirements and schedules:

Form	Route of Administration	Dosing Regimen
Oral Tablet	Swallowed	200 mg loading dose (Day 1), then 100 mg maintenance dose once daily.
Topical Cream	Applied to skin	A thin layer applied twice daily (morning and evening).
IV Solution	Intravenous Infusion	200 mg administered over 60 minutes, every 12 hours.

Administration Specifics

Oral Tablets

The oral tablet may be taken with or without food. The film-coated tablet must be swallowed whole; it is not to be crushed or chewed. The once-daily dose should be taken at approximately the same time each day.

Intravenous (IV) Solution

The IV solution is supplied as a concentrate and must be properly diluted before administration. The concentrate is to be diluted in either 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection (Normal Saline) to a final concentration that does not exceed 0.5 mg/mL. The diluted solution must then be administered slowly into a vein using a controlled infusion pump over a period of at least 60 minutes. The IV solution is incompatible with bicarbonate-containing solutions and must not be mixed with other medications in the same line.

Population and Duration Rules

Dose Adjustments: Patients with severe kidney impairment, specifically those with a calculated creatinine clearance of less than 50 mL/min, may require a reduction in the IV dose to 100 mg every 24 hours. Pediatric dosing is determined based on the patient's body surface area (BSA) or weight (e.g., 3 mg/kg once daily).

Treatment Duration: The duration of treatment is typically determined by the clinical response, but often ranges from 14 to 28 days for systemic use. Topical application may continue for up to one week after symptoms clear, with treatment not to exceed four weeks.

The name Fungram refers to a hypothetical or investigational antifungal agent, and therefore, specific clinical trial data for a drug named Fungram are not available in major public health databases. However, an examination of recent clinical evidence for novel antifungal agents provides context for the current landscape of fungal infection treatment.

Antifungal research is primarily focused on addressing the growing concern of drug-resistant fungal pathogens, such as Candida auris and azole-resistant Aspergillus fumigatus. The development pipeline is concentrated on new classes of drugs that target different biological pathways in the fungal cell than existing polyenes, azoles, and echinocandins.

Key Areas of Recent Antifungal Research

Recent clinical trials have focused on next-generation agents with activity against resistant and difficult-to-treat infections. These agents often offer novel mechanisms of action or improved administration profiles (e.g., oral formulations for systemic infections).

Novel Antifungal Agent Class	Examples in Clinical Trials	Clinical Focus
Echinocandins (Next-Gen)	Rezafungin	Invasive candidiasis, candidemia
Triterpenoids	Ibrexafungerp	Vulvovaginal candidiasis, multidrug-resistant fungi
Orotomides	Olorofim	Invasive aspergillosis, rare/refractory fungal diseases
Gwt1 Inhibitors	Fosmanogepix	Candidemia, invasive fungal infections

These studies, ranging from Phase 2 to Phase 3, aim to establish the efficacy (ability to treat the infection) and safety profile of new compounds. For example, some agents demonstrate potent activity against resistant Candida species and offer a favorable route of administration, such as an oral option that allows patients to transition from intravenous therapy sooner. Data collection continually monitors for adverse events, including effects on the liver or kidneys, which are common concerns with older antifungal classes.

Common questions about Fungram (FAQ)

Q: How quickly can a person generally expect to notice the initial effects of Fungram?

According to official regulatory data, relief for some fungal infections is supported by clinical data shortly after treatment is started. For example, official reports indicate that following a single oral dose, the median time to notice initial symptom relief is about one day.

---

Q: Does Fungram carry a 'Black Box Warning' in regulatory documents like the FDA's?

Official prescribing information from the FDA does not list an explicit Black Box Warning for Fungram. However, regulatory documents do contain serious safety warnings concerning potential problems with the heart (cardiac toxicity) and the liver (hepatic toxicity) that are noted in regulatory information.

---

Q: What official guidance is provided regarding the use of alcohol while taking Fungram?

Official drug labels generally do not provide direct instructions regarding the use of alcohol. However, since Fungram can potentially strain the liver and may cause side effects like dizziness, regulatory documents indicate that caution may be appropriate.

---

Q: How is the long-term safety of Fungram addressed in published regulatory summaries?

The safety profile that underpins regulatory approval is supported by nonclinical toxicology studies, which form the basis for regulatory summaries. These studies include tests on animals that have lasted up to 24 months to address the effects of long-term use.

---

Q: Is Fungram easily absorbed by the body, or is its bioavailability a concern?

Official pharmacokinetic data shows that Fungram is very well-absorbed when taken by mouth. The amount of drug that successfully enters the bloodstream (bioavailability) is reported to be over 90% compared to when the drug is given intravenously.

---

Q: How long does it typically take for Fungram to be fully eliminated from the body?

Fungram has a long half-life. For healthy individuals, the time it takes for half of the drug to be eliminated from the bloodstream is approximately 30 hours, though this can vary.

---

Q: Are there specific warnings about discontinuing Fungram abruptly?

While general warnings about abruptly stopping the drug may not be provided in regulatory documents, the official information notes a key factor for discontinuation. The drug's enzyme-inhibiting effect can persist for 4 to 5 days after the last dose due to its long half-life.

---

Q: Is Fungram classified as a short-term or long-term medication?

Fungram is typically used for finite, condition-dependent treatments rather than permanent, long-term use. Due to its 30-hour half-life, the drug reaches its full, stable concentration (steady-state) in the bloodstream relatively quickly, usually within 5 to 10 days of starting once-daily administration.

---

Q: Are there any specific side effects related to changes in mood or sleep when using Fungram?

According to official safety information, Insomnia (difficulty sleeping) is listed as an Uncommon side effect. Other reactions affecting the nervous system, such as dizziness and seizures, have also been reported in regulatory documents.

---

Q: Does Fungram have known interactions with common over-the-counter pain medications?

Regulatory documents indicate that Fungram can affect how the body processes certain common over-the-counter pain relievers, specifically those containing ibuprofen. Fungram is known to increase the amount of ibuprofen circulating in the body by inhibiting the enzyme CYP2C9.

How to Store and Dispose of Fungram?

Official regulatory guidelines mandate specific conditions to ensure the stability and safe handling of Fungram (Fluconazole) formulations.

Storage Condition	Requirement (Regulatory Labeling)
Temperature (Solid Forms/Dry Powder)	Store below 30 C (86 F).
Temperature (Reconstituted Suspension)	Store between 5 C and 30 C (41 F and 86 F). Do not freeze.
Protection	Keep in its original pack, protected from moisture and excessive heat or sunlight.
Stability Limit	Discard the unused portion of the reconstituted oral suspension after 2 weeks (14 days). Do not use after the expiry date.
Child Safety	Keep the medicine out of the sight and reach of children.

Expired or unused Fungram must be discarded according to local guidelines, often by returning it to a pharmacist for disposal. Specific instructions apply for the safe handling and discarding of used needles, syringes, and containers associated with the solution for injection.